Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice

Pharmacological Reports

Volumn 62, Issue 4, 2010, Pages 627-634

  Talarek, Sylwia ^a   Orzelska, Jolanta ^a   Listos, Joanna ^a   Fidecka, Sylwia ^a  

^a Department of Pharamacology and Pharmacodynamics   (Poland)

Author keywords

Diazepam; Mice; Motor impairment; Sedation; Sildenafil; Tolerance

Indexed keywords

DIAZEPAM; SILDENAFIL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; EVENING DOSAGE; LOCOMOTION; LONG TERM EXPOSURE; MALE; MORNING DOSAGE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; ROTAROD TEST; SEDATION;

EID: 77958015173     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70320-0     Document Type: Article

References (46)

1. Allison C, Pratt JA: Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther, 2003, 98, 171-195.
2. Abdel-Zaher AO, Hamdy MH, Aly SA, Abdel-Hady RH, Abdel-Rahman S: Attenuation of morphine tolerance and dependence by aminoguanidine in mice. Eur J Pharmacol, 2006, 540, 60-66.
3. Babey AM, Kolesnikov Y, Cheng J, Inturrisi CE, Trifilletti RR, Pasternak GW: Nitric oxide and opioid tolerance. Neuropharmacology, 1994, 33, 1463-1470.
4. Bateson AN: Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des, 2002, 8, 5-21.
5. Bezerra MM, Lima V, Girao VCC, Teixeira RC, Graça JRV: Antinociceptive activity of sildenafil and adrenergic agents in the writhing test in mice. Pharmacol Rep, 2008, 60, 339-3444.
6. Bonavita CD, Bisagno V, Bonelli CG, Acosta GB, Rubio MC, Wikinski SI: Tolerance to the sedative effect of lorazepam correlates with a diminution in cortical release and affinity for glutamate. Neuropharmacology, 2002, 42, 619-625.
7. Bruckdorfer R: The basics about nitric oxide. Mol Aspects Med, 2005, 26, 3-31.
8. Dawson TD, Snyder SH: Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci, 1994, 14, 5147-5159.
9. Esplugues JV: NO as a signalling molecule in the nervous system. Br J Pharmacol, 2002, 135, 1079-1095.
10. Fernandes C, Arnot MI, Irvine EE, Bateson AN, Martin IL, File SE: The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology, 1999, 145, 251-259.
11. Fernandes C, File SE: Dizolcipine does not prevent of tolerance to the anxiolytic effects of diazepam in rats. Brain Res, 1999, 815, 431-434.
12. File SE: Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 1985, 9, 113-121.
13. Gallager DW, Lakoski JM, Gonsalves SF, Rauch, SL: Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature, 1984, 308, 74-77.
14. Goldenberg MM: Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther, 1998, 20, 1033-1048.
15. Guevara-Guzman R, Emson CP, Kendrick KM: Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J Neurochem, 1994, 62, 807-810.
16. Guix FX, Uribesalgo I, Coma M, Muńoz FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol, 2005, 76, 126-152.
17. Ignarro LJ: Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Seminars Haematol, 1989, 26, 63-76.
18. Jain NK, Patil CS, Singh A, Kulkarni SK: Sildenafilinduced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res, 2001, 170-178.
19. Katzung BG: Basic and clinical pharmacology. Appleton and Lange, Norwalk, CT, 1995.
20. Khanna JM, Morato GS, Chau A, Shah G: Influence of nitric oxide synthase inhibition on the development of rapid tolerance to ethanol. Brain Res Bull, 1995, 37, 599-604.
21. Kippin TE, Pinell JJP, Kornecook TJ, Kalynchuk LE: Noncontingent drug exposure facilitates the development of contingent tolerance to the anticonvulsant effects of ethanol and diazepam in kindled rats. Pharmacol Biochem Behav, 1998, 61, 143-148.
22. Lue WM., Su MT, Lin WB, Tao PT: The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices. Eur J Pharmacol, 1999, 383, 129-135.
23. Majeed NH, Przewłocka, B, Machelska, H, Przewłocki, R: Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology, 1994, 33, 189-199.
24. Möhler H: GABA A receptor diversity and pharmacology. Cell Tissue Res, 2006, 326, 505-516.
25. Nidhi G, Bhargava VK, Pandhi P: Tolerance to and withdrawal from anticonvulsant action of diazepam: role of nitric oxide. Epilepsy Behav, 2000, 1, 262-270.
26. Phillips BG, Kato M, Pesek, CA, Winnicki, M, Narkiewicz, K, Davison, D, Somers, VK: Sympathetic activation by sildenafil. Circulation, 2000, 102, 3068-3073.
27. Quock, RM, Nquyen, E: Possible involvement of nitric oxide in chlordiazepoxide-induced anxiolysis in mice. Life Sci, 1992, 51, PL255-260.
28. Riazi K, Roshanpour M, Rafiei-Tabatabei N, Homayoun H, Ebrahimi F, Dehpour AR: The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br J Pharmacol, 2006, 147, 935-943.
29. Segovia G, Porras A, Mora F: Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. NeuroReport, 1994, 5, 1937-1940.
30. Smith RL, Barrett RJ: Tolerance to the anticonflict effects of diazepam: Importance of methodological considerations. Pharmacol Biochem Behav, 1997, 58, 61-66.
31. Stephens DN: A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav Pharmacol, 1995, 6, 425-446.
32. Tahsili-Fahadan P, Yahyavi-Firouz-Abadi N, Orandi AH, Esmaeili B, Basseda Z, Dehpour AR: Rewarding properties of sildenafil citrate in mice: role of the nitric oxidecyclic GMP pathway. Psychopharmacology, 2006, 185, 201-207.
33. Talarek S, Fidecka S: Involvement of nitricoxidergic system in the hypnotic effects of benzodiazepines in mice. Pol J Pharmacol, 2004, 56, 719-726.
34. Talarek S, Fidecka S: Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice. Pol J Pharmacol, 2003, 55, 181-191.
35. Talarek S, Fidecka S: Role of nitric oxide in benzodiazepines-induced antinociception in mice. Pol J Pharmacol, 2002, 54, 27-34.
36. Talarek S, Listos J, Fidecka S: Role of nitric oxide in the development of tolerance to diazepam-induced motor impairment in mice. Pharmacol Rep, 2008, 60, 475-482.
37. Tallman JF, GallagerDW: The GABAergic system: a locus of benzodiazepine action. Annu Rev Neurosci, 1985, 8, 21-44.
38. Tietz EI, Rosenberg HC, Chiu TH: Audiographic localization of benzodiazepine receptor down regulation. J Pharmacol Exp Ther, 1986, 236, 284-292.
39. Ulhayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M: Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep, 2007, 59, 150-163.
40. Uzbay IT, Oglesby MW: Nitric oxide and substance dependence. Neurosci Biobehav Rev, 2001, 25, 43-52.
41. A receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci, 2004, 24, 6785-6790.
42. Valtschanoff JG, Weinberg, RJ, Rustioni, A, Schmidt, HHHW: Nitric oxide synthase and GABAcolocalize in lamina 2 of rat spinal cord. Neurosci Lett, 1992, 148, 6-10.
43. Vogel HG, Vogel WH: Psychotropic and neurotropic activity. In: Drug discovery and evaluation. Pharmacological assays. Ed. Vogel HG, Vogel WH, Springer-Verlag, Berlin, Heidelberg, New York, 1997, 204-213.
44. A receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol, 2005, 5, 47-52.
45. Wazlawik E, Morato GS: Effect of intracerebroventricular administration of 7-nitroindazole on tolerance to ethanol. Brain Res Bull, 2002, 57, 165-170.
46. Zarri I, Bucossi G, Cupello A, Rapallino MV, Robello M: Modulation by nitric oxide of rat brain GABAA receptors. Neurosci Lett, 1994, 180, 239-242.